Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 5/20 | 0.42 |
| ▸ | TGM2 | P21980 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25259047 | 0.76 | TLR9 (0.41) | ALDH1A1LMNA | |
| SCHEMBL16645216 | 0.76 | TLR9 (0.41) | ALDH1A1LMNA | |
| SCHEMBL30327584 | 0.72 | SMN1; SMN2 (0.56) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL25289994 | 0.72 | SMN1; SMN2 (0.56) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL1237389 | 0.72 | SMN1; SMN2 (0.56) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15566863 | 0.70 | SMN1; SMN2 (0.67) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL22732073 | 0.70 | TEAD1 (0.43) | TEAD1TGM2ALDH1A1LMNAKMT2A | |
| SCHEMBL30368291 | 0.70 | SMN1; SMN2 (0.67) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL15566864 | 0.70 | SMN1; SMN2 (0.67) | TGM2ALDH1A1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL29445632 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| EP-4208448-B1 | ACRYLAMIDE DERIVATIVES | NRG THERAPEUTICS LTD (GB) | 2025-04-23 | — | — | EP | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| EP-4208448-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096712-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022049377-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312466-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | TEAD1 1423/4885TGM2 1886/4885ALDH1A1 516/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | TEAD1 3208/4885TGM2 1592/4885ALDH1A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.